MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

Subjects:

Mean scores, standard deviations, and significance on key measures and subscales by gender group. by Silas Manning (22693338)

Subjects:

Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

PRISMA flow chart. by Filip Stanicic (17808254)

Subjects:

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Subjects:

Mean standard errors across time points for the outcome of social stigma. by Ana Beato (20489933)

Subjects:

Means with standard errors across time points for the outcome of social distance. by Ana Beato (20489933)

Subjects:

Means with standard errors across time points for the outcome of intergroup anxiety. by Ana Beato (20489933)

Subjects:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Means with standard errors across time points for the outcome of mental health knowledge. by Ana Beato (20489933)

Subjects:

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Means for STEM competence for pre- and post-test. by Esther Kim (2996622)

Subjects:

Means for global competence pre- and post-test scores. by Esther Kim (2996622)

Subjects:

Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects: